Pinnacle Associates LTD Lexicon Pharmaceuticals, Inc. Transaction History

Pinnacle Associates LTD

$6.21 Billion
Q2 2024

A detailed history of Pinnacle Associates LTD transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Pinnacle Associates LTD holds 1,715,831 shares of LXRX stock, worth $2.75 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

1,715,831

Previous 1,747,830 1.83%

Holding current value

$2.75 Million

Previous $4.19 Million 31.28%

% of portfolio

0.05%

Previous 0.07%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	SELL	$1.54 - $2.28 $49,278 - $72,957	-31,999 Reduced 1.83%	1,715,831 $2.88 Million
Q1 2024 Apr 26, 2024	BUY	$1.3 - $3.58 $22,111 - $60,892	17,009 Added 0.98%	1,747,830 $4.19 Million
Q4 2023 Jan 19, 2024	SELL	$1.0 - $1.53 $182,048 - $278,533	-182,048 Reduced 9.52%	1,730,821 $2.65 Million
Q3 2023 Oct 23, 2023	SELL	$1.06 - $2.33 $85,603 - $188,166	-80,758 Reduced 4.05%	1,912,869 $2.09 Million
Q2 2023 Jul 26, 2023	BUY	$2.15 - $3.49 $114,816 - $186,376	53,403 Added 2.75%	1,993,627 $4.57 Million
Q1 2023 May 04, 2023	BUY	$1.99 - $2.68 $14,819 - $19,957	7,447 Added 0.39%	1,940,224 $4.71 Million
Q4 2022 Jan 31, 2023	SELL	$1.8 - $2.56 $91,341 - $129,907	-50,745 Reduced 2.56%	1,932,777 $3.69 Million
Q4 2022 Jan 25, 2023	SELL	$1.8 - $2.56 $85,833 - $122,073	-47,685 Reduced 2.35%	1,983,522 $0
Q3 2022 Oct 31, 2022	SELL	$1.94 - $3.43 $109,136 - $192,958	-56,256 Reduced 2.69%	2,031,207 $4.88 Million
Q2 2022 Aug 02, 2022	SELL	$1.31 - $2.69 $8,948 - $18,375	-6,831 Reduced 0.33%	2,087,463 $3.88 Million
Q1 2022 May 05, 2022	SELL	$1.95 - $3.89 $65,067 - $129,801	-33,368 Reduced 1.57%	2,094,294 $4.38 Million
Q4 2021 Feb 02, 2022	BUY	$3.81 - $6.16 $114,357 - $184,892	30,015 Added 1.43%	2,127,662 $8.38 Million
Q3 2021 Oct 19, 2021	SELL	$3.38 - $5.35 $314,796 - $498,272	-93,135 Reduced 4.25%	2,097,647 $10.1 Million
Q2 2021 Aug 02, 2021	BUY	$4.12 - $5.87 $97,273 - $138,590	23,610 Added 1.09%	2,190,782 $10.1 Million
Q1 2021 May 12, 2021	BUY	$3.45 - $9.09 $1.09 Million - $2.86 Million	314,790 Added 16.99%	2,167,172 $12.7 Million
Q4 2020 Jan 26, 2021	BUY	$1.05 - $3.67 $1.58 Million - $5.52 Million	1,505,122 Added 433.43%	1,852,382 $6.34 Million
Q3 2020 Oct 23, 2020	SELL	$1.44 - $2.1 $16,200 - $23,625	-11,250 Reduced 3.14%	347,260 $500,000
Q2 2020 Aug 14, 2020	BUY	$1.75 - $2.3 $3,788 - $4,979	2,165 Added 0.61%	358,510 $715,000
Q1 2020 May 13, 2020	SELL	$1.8 - $4.28 $77,452 - $184,164	-43,029 Reduced 10.77%	356,345 $695,000
Q4 2019 Feb 03, 2020	SELL	$3.16 - $5.15 $227,441 - $370,671	-71,975 Reduced 15.27%	399,374 $1.66 Million
Q3 2019 Nov 08, 2019	SELL	$1.2 - $6.66 $47,382 - $262,970	-39,485 Reduced 7.73%	471,349 $1.42 Million
Q2 2019 Aug 05, 2019	SELL	$5.35 - $7.11 $212,475 - $282,373	-39,715 Reduced 7.21%	510,834 $3.21 Million
Q1 2019 May 10, 2019	BUY	$4.36 - $7.94 $41,921 - $76,343	9,615 Added 1.78%	550,549 $3.06 Million
Q4 2018 Feb 05, 2019	SELL	$6.15 - $10.51 $232,377 - $397,120	-37,785 Reduced 6.53%	540,934 $3.59 Million
Q3 2018 Nov 13, 2018	SELL	$10.32 - $13.06 $991,813 - $1.26 Million	-96,106 Reduced 14.24%	578,719 $6.18 Million
Q2 2018 Aug 08, 2018	SELL	$7.8 - $13.69 $903,708 - $1.59 Million	-115,860 Reduced 14.65%	674,825 $8.1 Million
Q1 2018 May 11, 2018	SELL	$7.86 - $11.39 $499,031 - $723,151	-63,490 Reduced 7.43%	790,685 $6.78 Million
Q4 2017 Feb 12, 2018	SELL	$8.77 - $12.28 $375,969 - $526,443	-42,870 Reduced 4.78%	854,175 $8.44 Million
Q3 2017 Nov 13, 2017	BUY	$12.17 - $16.3 $2.22 Million - $2.97 Million	182,215 Added 25.49%	897,045 $11 Million
Q2 2017 Aug 09, 2017	BUY	N/A	714,830	714,830 $11.8 Million

Others Institutions Holding LXRX

# of Institutions

131

Shares Held

240M

Call Options Held

617K

Put Options Held

286K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $302M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.

Account

Pinnacle Associates LTD Lexicon Pharmaceuticals, Inc. Transaction History